2023
Factors associated with clinical trial participation for patients with renal cell carcinoma
Shinder B, Kim S, Srivastava A, Patel H, Jang T, Mayer T, Saraiya B, Ghodoussipour S, Singer E. Factors associated with clinical trial participation for patients with renal cell carcinoma. Urologic Oncology Seminars And Original Investigations 2023, 41: 208.e1-208.e8. PMID: 36868881, PMCID: PMC10106382, DOI: 10.1016/j.urolonc.2023.01.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Renal CellCase-Control StudiesHumansKidney NeoplasmsLogistic ModelsMaleMedicaidMedicareRetrospective StudiesUnited StatesConceptsRenal cell carcinomaCell carcinomaClinical trial participationClinical trialsOverall survivalClinical stageTrial patientsTrial participantsCharlson-Deyo comorbidity scoreAssociated with trial participationCompare overall survivalNational Cancer DatabaseLog-rank testClinical trial patientsPatient sociodemographic factorsAssociated with clinical trial participationMedian OSSuperior OSCancer DatabaseOncology clinical trialsSurvival outcomesMale patientsCase-control designPatient cohortControl cohort
2022
Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma
Patel HV, Kim S, Srivastava A, Shinder BM, Sterling J, Saraiya B, Mayer TM, Ghodoussipour S, Jang TL, Singer EA. Factors Associated With Palliative Intervention Utilization for Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2022, 20: 296-296.e9. PMID: 35105510, PMCID: PMC9149103, DOI: 10.1016/j.clgc.2022.01.001.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellCohort StudiesHumansKidney NeoplasmsNeoplasm StagingQuality of LifeConceptsStage IV RCCMetastatic renal cell carcinomaNational Cancer DatabasePalliative interventionsRenal cell carcinomaMetastatic RCCClinical factorsCell carcinomaMultivariable logistic regression modelComprehensive cancer programsQuality of lifeLogistic regression modelsSarcomatoid histologyAdvanced malignanciesOverall cohortHigher education statusOncologic careInsurance statusCancer DatabaseCancer programsEarly initiationIntervention utilizationTreatment-specific mannerPatientsPI use
2020
Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond
Srivastava A, Patel HV, Kim S, Shinder B, Sterling J, Tabakin AL, Polotti CF, Saraiya B, Mayer T, Kim IY, Ghodoussipour S, Patel HD, Jang TL, Singer EA. Delaying surgery for clinical T1b-T2bN0M0 renal cell carcinoma: Oncologic implications in the COVID-19 era and beyond. Urologic Oncology Seminars And Original Investigations 2020, 39: 247-257. PMID: 33223368, PMCID: PMC7574787, DOI: 10.1016/j.urolonc.2020.10.012.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaUpstaging riskOverall survivalCell carcinomaNonclear cell renal cell carcinomaOrgan-confined renal cell carcinomaCox proportional hazards modelNational Cancer DatabaseCell renal cell carcinomaKaplan-Meier curvesProportional hazards modelSmall renal massesCOVID-19Logistic regression modelsPT3a upstagingDelaying surgeryPrimary endpointSecondary endpointsPatient comorbiditiesMeier curvesElective surgeryRadical nephrectomyTumor histologyClinical stageRCC patientsChallenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery.
Patel H, Shinder B, Srinivasan R, Singer E. Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery. Current Opinion In Oncology 2020, 32: 240-249. PMID: 32195679, PMCID: PMC9788417, DOI: 10.1097/cco.0000000000000621.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Renal CellChemotherapy, AdjuvantClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicCytoreduction Surgical ProceduresHumansKidney NeoplasmsNeoadjuvant TherapyNeoplasm MetastasisProtein Kinase InhibitorsRandomized Controlled Trials as TopicConceptsMetastatic renal cell carcinomaRenal cell carcinomaCell carcinomaBiology of metastatic renal cell carcinomaTreatment of metastatic renal cell carcinomaManagement of metastatic renal cell carcinomaTyrosine kinase inhibitor cabozantinibProgrammed cell death protein 1 antibodyIntroduction of novel therapiesCombination of axitinibFirst-line therapyUS Food and Drug AdministrationFood and Drug AdministrationCytoreductive surgeryAdvanced RCCSystemic therapyCombination therapySurvival benefitTargeted therapyPatient selectionTreatment paradigmNovel therapiesTherapeutic advancesCombinatorial therapyTreatment advances
2018
Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database
Farber NJ, Rivera-Núñez Z, Kim S, Shinder B, Radadia K, Sterling J, Modi PK, Goyal S, Parikh R, Mayer TM, Weiss RE, Kim IY, Elsamra SE, Jang TL, Singer EA. Trends and outcomes of lymphadenectomy for nonmetastatic renal cell carcinoma: A propensity score-weighted analysis of the National Cancer Database. Urologic Oncology Seminars And Original Investigations 2018, 37: 26-32. PMID: 30446458, PMCID: PMC6295174, DOI: 10.1016/j.urolonc.2018.10.004.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Renal CellDatabases, FactualFemaleHumansLymph Node ExcisionMaleMiddle AgedPropensity ScoreUnited StatesConceptsLymph node dissectionNonmetastatic renal cell carcinomaRenal cell carcinomaMedian overall survivalNational Cancer DatabaseOverall survivalCell carcinomaCancer DatabasePropensity score-weighted analysisLow-stage diseaseLN-positive patientsLymph node involvementCox regression analysisSubgroup of patientsT stages 1Contemporary practice patternsRegression analysisChi-square testOS benefitPotential overutilizationNode dissectionUnderwent surgeryNode involvementPatient demographicsPositive patients
2016
Treatment of Multifocal Renal Cell Carcinoma in a Solitary Kidney With Nivolumab
Shinder B, Farber N, Mayer T, Singer E. Treatment of Multifocal Renal Cell Carcinoma in a Solitary Kidney With Nivolumab. Clinical Genitourinary Cancer 2016, 15: e165-e167. PMID: 27396730, PMCID: PMC5083235, DOI: 10.1016/j.clgc.2016.04.013.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements